Alex Zhavoronkov· biogerontology·· 19 天前AI 评分38
英矽智能ISM6331入选ESMO关注名单
DelveInsight named five first-in-class programs to watch at ESMO 2026. ISM6331, our AI-designed pan-TEAD inhibitor in Phase I for mesothe...
AI 导读
DelveInsight 评选出 ESMO 2026 五大值得关注的首创药物项目。我们的 AI 设计泛 TEAD 抑制剂 ISM6331 位列其中，正处于针对间皮瘤和晚期实体瘤的 I 期临床阶段。马德里，10 月 23-27 日。 https://www.delveinsight.com/esmo-conference-2026/article/5-first-in-class-therapies-to-look-out-for-at-esmo-2026
来源：Alex Zhavoronkov · x.com